Tasigna viste virkning hos patienter med forskellige Bcr- Abl- mutationer, der associeres med imatinib- resistens, undtagen T315I.
Tasigna demonstrated efficacy in patients harboring a variety of Bcr-Abl mutations associated with imatinib resistance, except T315I.